The results of this cohort study suggest that individuals with type 2 diabetes who initiated treatment with empagliflozin or ...
No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.
Medpage Today on MSN4d
No Clear Winner in SGLT2 Showdown for Cardiovascular Disease"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce ...
Teams of researchers are investigating empagliflozin and dapagliflozin in patients with autosomal dominant polycystic kidney disease (AD PKD).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback